Omeros Shares Surge on FDA Approval For Yartemlea

Dow Jones

Dec 25, 2025

By Elias Schisgall

Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment.

The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year.

The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures.

The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 24, 2025 11:55 ET (16:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2594940514"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594940514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594940514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-25 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594940514","market":"us","top_or_hot":-1,"title":"Omeros Shares Surge on FDA Approval For Yartemlea","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. \n</p>\n<p>\n  The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year. \n</p>\n<p>\n  The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures. \n</p>\n<p>\n  The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 11:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Shares Surge on FDA Approval For Yartemlea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Shares Surge on FDA Approval For Yartemlea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-25 00:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. \n</p>\n<p>\n  The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year. \n</p>\n<p>\n  The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures. \n</p>\n<p>\n  The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 11:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594940514","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594940514","pubTimestamp":1766595300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment.The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year.The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures.The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OMER":"奥麦罗制药"},"translate_title":"FDA批准Yartemlea后Omeros股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. \n\n\n  The stock was up 78% to $15.60 on Wednesday and was briefly paused for volatility. Shares have risen 56% this year. \n\n\n  The Seattle-based pharmaceutical company said Wednesday that the FDA greenlit Yartemlea for patients ages 2 and older who experience a serious complication from stem-cell transplant procedures. \n\n\n  The FDA approval makes Yartemlea the only approved treatment that works by inhibiting the effector enzyme of the lectin pathway, Omeros said. It said it is finalizing preparations for a product launch in the U.S. next month. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 24, 2025 11:55 ET (16:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}